Meeting
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
Authors
Yara L. Verschoor
Netherlands Cancer Institute, Amsterdam, Netherlands
Yara L. Verschoor , José van den Berg , Geerard Beets , Karolina Sikorska , Arend Aalbers , Anja van Lent , Cecile Grootscholten , Inge Huibregtse , Hendrik Marsman , Steven Oosterling , Marieke van de Belt , Marleen Kok , Ton Schumacher , Monique E van Leerdam , Emile E. Voest , Myriam Chalabi , John B. A. G. Haanen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT03026140
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3511)
DOI
10.1200/JCO.2022.40.16_suppl.3511
Abstract #
3511
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb
Poster
2019 ASCO Annual Meeting
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris